Loading…
Loading…
PSYK (PSYK ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
The fund adviser uses a “passive management” (or indexing) approach to track the performance of the index. The index is a rules-based index that tracks the performance of a portfolio of companies that have business activity in the fields of psychedelic treatment used to address medical conditions in legal pharmacological applications under the applicable country’s laws. The fund will generally invest in all of the component securities of the index in the same approximate proportions as in the index. It is non-diversified.
Is PSYK's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.
A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF PSYK tracks the Enhanced Consciousness Index.
First-time issuer Elemental Advisors is the latest to create an ETF for the burgeoning industry.
Elemental Advisors just launched the PSYK ETF (NYSE Arca: PSYK), a thematic ETF focused on the emerging use of psychedelic compounds in treating mental health issues. Tim Collins, a founder and president of Elemental Advisors, recently provided some insight as to why the company decided to make this its first issued ETF, how the medicinal [.